Brasilia, Brazil – On October 30, WALTZ™ CoCr Coronary Stent System ("WALTZ™"), in-house developed by Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"), received approval from Brazil's National Health Surveillance Agency (in Portuguese, Agência Nacional de Vigilância Sanitária - ANVISA). The product had received CE mark and gained regulatory approvals in Argentina, Peru, the Philippines, Indonesia, and etc.
WALTZ™ is indicated for the treatment of coronary artery stenosis or occlusion. It has L605 Cobalt-Chromium alloy stent architecture with three different stent designs. As the third-generation bare metal stent of MicroPort®, WALTZ™ has strong radial strength and excellent flexibility, crossability, trackability, and pushability to achieve the best surgical outcome.
Aside from WALTZ™, MicroPort®’s Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"), Firefighter™ PTCA Balloon Dilatation Catheter ("Firefighter™ PTCA"), and other coronary interventional products also obtained regulatory approval in Brazil. As WALTZ™ is permitted to be officially launched in the Brazil market, MicroPort® will further diversify its cardiovascular product line with accelerated product upgrading. With its outstanding performance, WALTZ™ is expected to help MicroPort® further consolidate and expand its coronary products' market share in Brazil and other the overseas markets.